Results 181 to 190 of about 41,531 (223)

Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva. [PDF]

open access: yesClin Pharmacokinet
Nguyen TA   +10 more
europepmc   +1 more source

Occurrence of oxazolidinone resistance genes in enterococci, staphylococci, and Mammaliicoccus sciuri from swine slaughterhouse wastewater, Italy. [PDF]

open access: yesWorld J Microbiol Biotechnol
Massacci FR   +14 more
europepmc   +1 more source

Bilateral optic neuropathy following prolonged linezolid use: A case report. [PDF]

open access: yesIDCases
Ibrahim HO   +5 more
europepmc   +1 more source

Linezolid-mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition. [PDF]

open access: yesArthritis Rheumatol
Hong X   +13 more
europepmc   +1 more source

When antibiotics turn red: A case of piperacillin-tazobactam-induced baboon syndrome. [PDF]

open access: yesJ Allergy Clin Immunol Glob
Bernaola M   +5 more
europepmc   +1 more source

Linezolid

open access: yesReactions Weekly, 2020
Linezolid is a synthetic oxazolidinone antimicrobial drug. It is indicated for gram-positive infections and approved for the treatment of bacterial pneumonia, skin and skin structure infections, and vancomycin-resistant enterococcal (VRE) infections ...
Azzouz, Angela, Preuss, Charles V
core   +5 more sources

Linezolid

Drugs, 2012
Anthony Markham   +2 more
exaly   +4 more sources

Linezolid

Drugs, 2000
Linezolid is an oxazolidinone antibacterial agent that acts by inhibiting the initiation of bacterial protein synthesis. Cross-resistance between linezolid and other inhibitors of protein synthesis has not been demonstrated. Linezolid has a wide spectrum of activity against gram-positive organisms including methicillin-resistant staphylococci ...
D, Clemett, A, Markham
openaire   +2 more sources

Pharmacoeconomics of linezolid

Expert Opinion on Pharmacotherapy, 2008
New antibiotics efficacious in infections caused by resistant Gram-positive microorganisms and with acceptable costs for national health systems per unit of effectiveness are needed.This paper aimed to summarize all available evidence regarding the pharmacoeconomics of linezolid.A systematic review of pharmacoeconomic analyses through a non-restricted ...
Santiago, Grau, Carlos, Rubio-Terrés
openaire   +2 more sources

Home - About - Disclaimer - Privacy